China cleared Lilly’s weight-loss pill a week after CIIE. The BMI line stayed American.
Orforglipron is China’s first oral GLP-1 for weight loss. The NMPA label still starts at BMI 27/30, while Novo’s injection was rewritten last month to China’s 24/28 scale.
On 5 November, at the China International Import Expo, reporters were still being told that Lilly’s orforglipron had finished technical review and was not yet approved. Seven days later the National Medical Products Administration published the decision: orforglipron calcium tablets, brand Muyouda (穆优达), a Class 1 drug for long-term weight management in adults. Lilly’s own China statement calls it the first oral GLP-1 cleared in the country for that use, and one of the first markets anywhere to grant it.
The approval is not the part that will decide the launch. The cutoff is.
NMPA’s notice uses the Western line: starting BMI of 30 or higher, or from 27 up to 30 if the patient already has a weight-related condition such as hypertension, dyslipidemia, or hyperglycemia. China’s 2024 obesity guideline draws the map differently—overweight from 24, obesity from 28. A large group that Chinese endocrinologists already call overweight never enters this label.
Novo moved first on that local map. On 21 October the company said NMPA had updated Wegovy’s China indication (诺和盈, semaglutide 2.4 mg) to BMI of 28 or above, or 24 up to 28 with a comorbidity, and it tied the change explicitly to the national guideline, citing the China-inclusive STEP 12 study. Lilly now has the oral product. Novo already has the BMI band where more Chinese patients sit.
The pill’s practical edge is real and narrow. It is a non-peptide small molecule, one tablet a day, with no fasting window—the contrast Lilly keeps drawing with oral semaglutide, which is a peptide and has to be taken on an empty stomach. In ATTAIN-1, Lilly says patients who stayed on the top dose for 72 weeks lost 12.4 kg on average, and about 40% lost at least 15%. Chinese business coverage says Novo has already filed its own oral weight-loss semaglutide in China; if that file clears in 2027, the head start is measured in months, not in a category Lilly owns. The diabetes use of orforglipron is still in NMPA review. Price, hospital listing, and whether departments will prescribe against a label that starts above the guideline they use have not been answered in the approval notice.
Industry information only—not medical or investment advice.
